Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Proficio Capital Partners LLC

Proficio Capital Partners LLC lowered its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 34.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,065 shares of the medical equipment provider’s stock after selling 568 shares during the period. Proficio Capital Partners LLC’s holdings in Intuitive Surgical were worth $523,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Field & Main Bank increased its position in shares of Intuitive Surgical by 0.7% during the third quarter. Field & Main Bank now owns 3,396 shares of the medical equipment provider’s stock worth $1,668,000 after purchasing an additional 24 shares in the last quarter. Objective Capital Management LLC acquired a new stake in shares of Intuitive Surgical during the third quarter worth about $467,000. Bridges Investment Management Inc. increased its position in shares of Intuitive Surgical by 10.5% during the third quarter. Bridges Investment Management Inc. now owns 175,266 shares of the medical equipment provider’s stock worth $86,103,000 after purchasing an additional 16,675 shares in the last quarter. Klingman & Associates LLC grew its holdings in shares of Intuitive Surgical by 6.5% during the third quarter. Klingman & Associates LLC now owns 725 shares of the medical equipment provider’s stock worth $356,000 after buying an additional 44 shares during the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Intuitive Surgical by 21.8% during the third quarter. Assetmark Inc. now owns 81,554 shares of the medical equipment provider’s stock worth $40,065,000 after buying an additional 14,595 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In related news, CEO Gary S. Guthart sold 18,151 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total value of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Gary S. Guthart sold 18,151 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was sold at an average price of $511.63, for a total value of $9,286,596.13. Following the sale, the chief executive officer now owns 24,219 shares of the company’s stock, valued at approximately $12,391,166.97. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $506.52, for a total value of $95,225.76. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,788,899.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 68,006 shares of company stock valued at $33,727,766. 0.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Stifel Nicolaus raised their price target on Intuitive Surgical from $475.00 to $525.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Wells Fargo & Company raised their price target on Intuitive Surgical from $466.00 to $549.00 and gave the stock an “overweight” rating in a report on Friday, October 18th. Morgan Stanley raised their price target on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Mizuho raised their price target on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Finally, Leerink Partners raised their price target on Intuitive Surgical from $489.00 to $502.00 in a report on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $513.74.

Intuitive Surgical Price Performance

ISRG opened at $536.45 on Monday. The stock has a market cap of $191.07 billion, a P/E ratio of 86.25, a P/E/G ratio of 5.27 and a beta of 1.39. The stock’s 50 day simple moving average is $493.92 and its 200 day simple moving average is $452.25. Intuitive Surgical, Inc. has a 1-year low of $269.49 and a 1-year high of $538.49.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The firm had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Research analysts expect that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.